Text Size A A A

Sun Pharma In The News

Tell a Friend Print Home » Media » Sun Pharma In The News

Sun Pharma gets USFDA approval for Prometh syrup

Drug major Sun Pharma on Thursday said it has received approval from the US health regulator for generic version of anti-alletrgic product Prometh syrup. The United States Food and Drug Administration (FDA) has granted an approval to the company's subsidiary for the syrup, Sun Pharmaceutical Industries Ltd said in a statement to the Bombay Stock Exchange. The company's product - Promethazine Hydrochloride and Codeine Phosphate Oral Syrup - is a bio-equivalent to Prometh. It has annual sales of about $16 million in the US. The medicine is used to treat symptoms caused by common cold, flu, allergies or other breathiing problems. Shares of Sun Pharma closed at Rs 1,693, down 0.04 per cent on the BSE.